Global /United States /Healthcare /Biotechnology /NKTX

Nkarta, Inc.

NKTX

• NASDAQ: NKTX • Delayed

2.69USD -2.9%

As of 13 June 2026, Nkarta, Inc. has a market cap of $191.77M USD, ranking #21344 globally and #3471 in the United States. It ranks #1908 in the Healthcare sector, and #368 in the Biotechnology industry.

Global Rank

21344

Country Rank

3471

Sector Rank

1908

Industry Rank

368

Key Stats

Market Cap

$191.77MUSD

Enterprise Value

-$12.37MUSD

EBITDA (TTM)

-$106.65MUSD

Net Income (TTM)

-$104.08MUSD

PB Ratio

0.6

Company Profile

Country (HQ)

United States

Sector

Healthcare

Industry

Biotechnology

CEO

Paul Hastings open_in_new

Employees

108

Founded

2015

IPO

10 Jul 2020

Website

nkartatx.com open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
-2.9%	-20%	29%	7.3%	15%	43%	32%	-46%	-92%

News

NKTX Analyst Forecasts

Markets

Exchange	Ticker	Price	Quotes
NASDAQ MIC: XNAS PRIMARY	NKTX Nkarta Inc Ordinary Shares ISIN: US65487U1088 Shares Out.: Shares Outstanding: 71.545M¹ Shares Float: 54.303M² TV: TradingView: NASDAQ: NKTX SA: Stock Analysis: NASDAQ: NKTX YF: Yahoo Finance: NKTX GF: Google Finance: NASDAQ: NKTX NQ: NASDAQ: NKTX BA: Barron's: NKTX MS: Morningstar: XNAS: NKTX	2.69 USD	TV: TradingView: NASDAQ: NKTX SA: Stock Analysis: NASDAQ: NKTX YF: Yahoo Finance: NKTX GF: Google Finance: NASDAQ: NKTX NQ: NASDAQ: NKTX BA: Barron's: NKTX MS: Morningstar: XNAS: NKTX

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About Nkarta, Inc.

Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.

Similar Companies

Industry: Biotechnology (United States)

Name	Market Cap (USD) diff.	PE	Country
Amgen Inc. NASDAQ: AMGN	$182.42B 95K%	23.9	United States
Gilead Sciences, Inc. NASDAQ: GILD	$159.92B 83K%	19.0	United States
Natera, Inc. NASDAQ: NTRA	$27.6B 14K%	-	United States
IQVIA Holdings Inc. NYSE: IQV	$26.3B 14K%	20.0	United States
United Therapeutics Corp. NASDAQ: UTHR	$25.03B 13K%	20.4	United States
Moderna, Inc. NASDAQ: MRNA	$18.13B 9K%	-	United States

Industry: Biotechnology (Global)

Name	Market Cap (USD) diff.	PE	Country
argenx SE EBR: ARGX	$47.84B 41.39B EUR 25K%	39.9	Netherlands
Samsung Biologics Co.,Ltd. KRX: 207940	$44.84B 68.19T KRW 23K%	35.5	South Korea
CSL Ltd. ASX: CSL	$42.36B 60.27B AUD 22K%	29.3	Australia
Lonza Group AG SIX: LONN	$42.3B 33.71B CHF 22K%	37.2	Switzerland
Celltrion, Inc. KRX: 068270	$28.11B 42.76T KRW 15K%	43.8	South Korea
BioNTech SE NASDAQ: BNTX	$25.69B 13K%	-	Germany

chevron_leftBack